NICE needs more rimonabant data

Rimonabant should not be used for the treatment of obese and overweight adults, says NICE.

More information on how the drug compares to diet and exercise, orlistat and sibutramine with regards to cost effectiveness is needed from manufacturers Sanofi Aventis, claimed NICE in a draft technology appraisal issued last week.

NICE also wants an assessment of the drug using the 5 per cent weight loss continuation rule to treatment with rimonabant at three, six, nine and 12 months.

Jeni Wilson, head of communications at Sanofi Aventis said: 'The consultation document represents the preliminary feedback of the appraisal committee and is not formal guidance on this technology.

'The preliminary thoughts of the committee may change after consultation.'

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Dr Zoe Norris

GPDF slashes costs and overhauls funding rules to 'restore trust' with GPs

The General Practice Defence Fund (GPDF) has cancelled contracts worth hundreds of...

Churchill Gardens

Scheme from Brazil helps address health inequalities in London practice

A scheme involving community health and wellbeing workers, which is based on a long-standing...

Talking General Practice logo

Podcast: How an initiative from Brazil could help general practice and improve outcomes

Dr Matt Harris and London GP Dr Connie Junghans Minton explain how an initiative...

Medical centre sign

One in three GP practices in Northern Ireland faced serious closure risk in past 18 months

One in three GP practices in Northern Ireland have faced a serious risk of closure...

BMA sign

BMA warns Treasury 'many practices' will close without emergency financial support

GP leaders have urged the Treasury to agree emergency funding to support general...


Practices can use £172m PCN cash to support staff pay rises, GP leaders say

Practices can use their share of Β£172m from the 2023/24 investment and impact fund...